Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.44 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.44 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30795980 | 1.00 | CTNNB1 (0.47) | CTNNB1TCF7L2SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL30824680 | 0.90 | S1PR3 (0.42) | CTNNB1TCF7L2SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL22271 | 0.90 | S1PR3 (0.42) | CTNNB1TCF7L2SLC2A1SLC2A2SLC2A3 | |
| SCHEMBL30795753 | 0.85 | L3MBTL1 (0.48) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL22343 | 0.85 | L3MBTL1 (0.48) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL30795590 | 0.85 | SMN1; SMN2 (0.46) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL22402 | 0.85 | SMN1; SMN2 (0.46) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL22217 | 0.85 | KCNQ3 (0.55) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL30824643 | 0.85 | KCNQ3 (0.55) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB | |
| SCHEMBL22717 | 0.83 | SMN1; SMN2 (0.44) | CTNNB1TCF7L2SMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609085-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| US-8445512-B2 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-05-21 | — | — | US | claimed |
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | claimed |
| WO-2012025238-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | claimed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |
| EP-2609085-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8445512-B2 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025238-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | CTNNB1 3098/4885TCF7L2 2695/4885SLC2A1 1707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.